within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01C_PlantAlkaloidsAndOtherNaturalProducts.L01CD51_PaclitaxelAndEncequidar;

model PaclitaxelAndEncequidar
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.4,
    Cl = 2.6666666666666664e-06,
    adminDuration = 600,
    adminMass = 205 / 1000000,
    adminCount = 1,
    Vd = 0.241,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.005333333333333333,
    Tlag = 10.200000000000001,
    Vdp = 0.212,
    k12 = 9.583333333333334e-06,
    k21 = 9.583333333333334e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>PaclitaxelAndEncequidar</td></tr><tr><td>ATC code:</td><td>L01CD51</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>205</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>241</td><td>L</td></tr>
    <tr><td>clearance:</td><td>9.6</td><td>L/hr</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Paclitaxel and encequidar is an orally administered combination product for cancer treatment. Paclitaxel is a microtubule inhibitor used in treatment of ovarian, breast, and other cancers. Encequidar is a P-glycoprotein inhibitor that increases the bioavailability of paclitaxel by inhibiting intestinal efflux, thereby enabling oral administration. The combination has received regulatory approval (e.g., FDA) for metastatic breast cancer in certain scenarios.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adults with advanced solid tumors; population PK analysis of oral paclitaxel with encequidar co-administration.</p><h4>References</h4><ol><li><p>He, J, et al., &amp; Zhi, J (2022). Population pharmacokinetics for oral paclitaxel in patients with advanced/metastatic solid tumors. <i>CPT: pharmacometrics &amp; systems pharmacology</i> 11(7) 867–879. DOI:<a href=\"https://doi.org/10.1002/psp4.12799\">10.1002/psp4.12799</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35470967/\">https://pubmed.ncbi.nlm.nih.gov/35470967</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01CD51 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end PaclitaxelAndEncequidar;
